Sino Biopharmaceutical Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sino Biopharmaceutical Limited's yearly results (2022–2025), compared with companies in Hong Kong. Tap ? on any ratio for what it means.
Where ¥100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥269Over the last 3 years, every ¥100 of reported profit came with ¥269 of operating cash.
Higher than 82% of companies in Hong Kong.
Self-Funding Ratio
4.6×Over the last 3 years its own operating cash covered its investment spending (capex) 4.6 times.
Higher than 72% of companies in Hong Kong.
Cash Locked Ratio
¥5For every ¥100 of sales, ¥5 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥8 tied up three years earlier.
More money tied up than 68% of companies in Hong Kong.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 58% of companies in Hong Kong.
Growth Efficiency Ratio
−¥3Sales grew 22% in 3 years, but profit fell: ¥3 less profit per ¥100 of extra sales.
Lower than 75% of companies in Hong Kong.
Asset Productivity Ratio
+22% / +19%In 3 years sales changed by +22% while total assets changed by +19%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
1.1×Debt due within a year is covered 1.1 times by its yearly operating cash.
Lower than 64% of companies in Hong Kong.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
91%Of every ¥100 the company owns, ¥91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 71% of companies in Hong Kong.
Tangible Net Worth Ratio
77%Of every ¥100 of net worth, ¥77 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 68% of companies in Hong Kong.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Sino Biopharmaceutical Limited owes ¥0.45 for every ¥1 it owns. Net profit fell 33% in the year to Dec 2025, and shrank 3% a year on average over 3 years.
Compared with companies in Hong Kong · latest annual results Dec 2025.
P/E ratio
35.6Investors pay ¥35.6 for every ¥1 of Sino Biopharmaceutical Limited's yearly profit, higher than almost all companies in Hong Kong.
P/B ratio
2.46The share price is 2.46 times Sino Biopharmaceutical Limited's book value per share, higher than 88% of companies in Hong Kong.
Market cap
HK$88.7 BThe total market value of all of Sino Biopharmaceutical Limited's shares at today's price (share price × number of shares), smaller than 77% of companies in Hong Kong. PosiCap size class: Tito Cap.
Net worth (book value)
¥30.7 BWhat Sino Biopharmaceutical Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Dec 2025).
Return on equity (ROE)
14.1%Sino Biopharmaceutical Limited earned 14.1% on its shareholders' money over the last year, higher than 69% of companies in Hong Kong.
Owes vs Owns
0.45×Sino Biopharmaceutical Limited owes ¥0.45 for every ¥1 it owns (low), higher than 53% of companies in Hong Kong.
Dividend yield
2.62%Sino Biopharmaceutical Limited pays 2.62% of its share price as dividends a year, lower than 88% of dividend-paying companies in Hong Kong.
Revenue growth
+10%Revenue rose 10% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Profit growth
-33%Net profit fell 33% in the year to Dec 2025, and shrank 3% a year on average over 3 years.
Profit margin
7.4%Sino Biopharmaceutical Limited keeps ¥7 of every ¥100 of revenue as net profit.
Cash quality
4.0×Cash from Sino Biopharmaceutical Limited's business was 4.0× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
24.8×Sino Biopharmaceutical Limited's operating profit covered its interest costs 24.8 times in the year to Dec 2025.
Cash vs debt
Net cashSino Biopharmaceutical Limited held ¥6.9 B more cash than debt (net cash) at Dec 2025.
Questions
What is Sino Biopharmaceutical Limited's P/E ratio?
Investors pay ¥35.6 for every ¥1 of Sino Biopharmaceutical Limited's yearly profit, higher than almost all companies in Hong Kong.
What is Sino Biopharmaceutical Limited's return on equity?
Sino Biopharmaceutical Limited earned 14.1% on its shareholders' money over the last year, higher than 69% of companies in Hong Kong.
How much does Sino Biopharmaceutical Limited owe compared with what it owns?
Sino Biopharmaceutical Limited owes ¥0.45 for every ¥1 it owns (low), higher than 53% of companies in Hong Kong.
Does Sino Biopharmaceutical Limited pay a dividend?
Yes. Sino Biopharmaceutical Limited pays 2.62% of its share price as dividends a year, lower than 88% of dividend-paying companies in Hong Kong.
Is Sino Biopharmaceutical Limited's revenue growing?
Revenue rose 10% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.